Literature DB >> 31451537

Modeling Leukemia with Human Induced Pluripotent Stem Cells.

Eirini P Papapetrou1,2,3,4.   

Abstract

The reprogramming of human somatic cells into induced pluripotent stem cells (iPSCs) a little over a decade ago raised exciting prospects to transform the study and potentially also the therapy of human diseases. iPSC models have now been created for a multitude of hematologic diseases, including malignancies. Here we discuss practical aspects of iPSC modeling of malignant diseases, review recent studies, and discuss the new opportunities that iPSC models offer, as well as their current limitations and prospects for future development.
Copyright © 2019 Cold Spring Harbor Laboratory Press; all rights reserved.

Entities:  

Year:  2019        PMID： 31451537      PMCID： PMC6886454          DOI： 10.1101/cshperspect.a034868

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Med        ISSN： 2157-1422            Impact factor:   6.915


  101 in total

1.  A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity.

Authors:  Rosa M Marión; Katerina Strati; Han Li; Matilde Murga; Raquel Blanco; Sagrario Ortega; Oscar Fernandez-Capetillo; Manuel Serrano; Maria A Blasco
Journal:  Nature       Date:  2009-08-09       Impact factor: 49.962

Review 2.  Hemangioblast, hemogenic endothelium, and primitive versus definitive hematopoiesis.

Authors:  Georges Lacaud; Valerie Kouskoff
Journal:  Exp Hematol       Date:  2016-12-30       Impact factor: 3.084

Review 3.  A guide to genome engineering with programmable nucleases.

Authors:  Hyongbum Kim; Jin-Soo Kim
Journal:  Nat Rev Genet       Date:  2014-04-02       Impact factor: 53.242

4.  Stage-Specific Human Induced Pluripotent Stem Cells Map the Progression of Myeloid Transformation to Transplantable Leukemia.

Authors:  Andriana G Kotini; Chan-Jung Chang; Arthur Chow; Han Yuan; Tzu-Chieh Ho; Tiansu Wang; Shailee Vora; Alexander Solovyov; Chrystel Husser; Malgorzata Olszewska; Julie Teruya-Feldstein; Deepak Perumal; Virginia M Klimek; Alexandros Spyridonidis; Raajit K Rampal; Lewis Silverman; E Premkumar Reddy; Elli Papaemmanuil; Samir Parekh; Benjamin D Greenbaum; Christina S Leslie; Michael G Kharas; Eirini P Papapetrou
Journal:  Cell Stem Cell       Date:  2017-02-16       Impact factor: 24.633

5.  Targeted correction of RUNX1 mutation in FPD patient-specific induced pluripotent stem cells rescues megakaryopoietic defects.

Authors:  Jon P Connelly; Erika M Kwon; Yongxing Gao; Niraj S Trivedi; Abdel G Elkahloun; Marshall S Horwitz; Linzhao Cheng; P Paul Liu
Journal:  Blood       Date:  2014-09-18       Impact factor: 22.113

6.  Modeling familial cancer with induced pluripotent stem cells.

Authors:  Dung-Fang Lee; Jie Su; Huen Suk Kim; Betty Chang; Dmitri Papatsenko; Ruiying Zhao; Ye Yuan; Julian Gingold; Weiya Xia; Henia Darr; Razmik Mirzayans; Mien-Chie Hung; Christoph Schaniel; Ihor R Lemischka
Journal:  Cell       Date:  2015-04-09       Impact factor: 41.582

7.  Background mutations in parental cells account for most of the genetic heterogeneity of induced pluripotent stem cells.

Authors:  Margaret A Young; David E Larson; Chiao-Wang Sun; Daniel R George; Li Ding; Christopher A Miller; Ling Lin; Kevin M Pawlik; Ken Chen; Xian Fan; Heather Schmidt; Joelle Kalicki-Veizer; Lisa L Cook; Gary W Swift; Ryan T Demeter; Michael C Wendl; Mark S Sands; Elaine R Mardis; Richard K Wilson; Tim M Townes; Timothy J Ley
Journal:  Cell Stem Cell       Date:  2012-04-26       Impact factor: 24.633

8.  DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia.

Authors:  Maria E Figueroa; Sanne Lugthart; Yushan Li; Claudia Erpelinck-Verschueren; Xutao Deng; Paul J Christos; Elizabeth Schifano; James Booth; Wim van Putten; Lucy Skrabanek; Fabien Campagne; Madhu Mazumdar; John M Greally; Peter J M Valk; Bob Löwenberg; Ruud Delwel; Ari Melnick
Journal:  Cancer Cell       Date:  2010-01-07       Impact factor: 31.743

9.  Common genetic variation drives molecular heterogeneity in human iPSCs.

Authors:  Helena Kilpinen; Angela Goncalves; Andreas Leha; Vackar Afzal; Kaur Alasoo; Sofie Ashford; Sendu Bala; Dalila Bensaddek; Francesco Paolo Casale; Oliver J Culley; Petr Danecek; Adam Faulconbridge; Peter W Harrison; Annie Kathuria; Davis McCarthy; Shane A McCarthy; Ruta Meleckyte; Yasin Memari; Nathalie Moens; Filipa Soares; Alice Mann; Ian Streeter; Chukwuma A Agu; Alex Alderton; Rachel Nelson; Sarah Harper; Minal Patel; Alistair White; Sharad R Patel; Laura Clarke; Reena Halai; Christopher M Kirton; Anja Kolb-Kokocinski; Philip Beales; Ewan Birney; Davide Danovi; Angus I Lamond; Willem H Ouwehand; Ludovic Vallier; Fiona M Watt; Richard Durbin; Oliver Stegle; Daniel J Gaffney
Journal:  Nature       Date:  2017-05-10       Impact factor: 49.962

10.  Dissecting the Contributions of Cooperating Gene Mutations to Cancer Phenotypes and Drug Responses with Patient-Derived iPSCs.

Authors:  Chan-Jung Chang; Andriana G Kotini; Malgorzata Olszewska; Maria Georgomanoli; Julie Teruya-Feldstein; Henrik Sperber; Roberto Sanchez; Robert DeVita; Timothy J Martins; Omar Abdel-Wahab; Robert K Bradley; Eirini P Papapetrou
Journal:  Stem Cell Reports       Date:  2018-04-19       Impact factor: 7.765
View more
  1 in total

1.  Studying leukemia stem cell properties and vulnerabilities with human iPSCs.

Authors:  Nikolaos Spyrou; Eirini P Papapetrou
Journal:  Stem Cell Res       Date:  2020-12-10       Impact factor: 1.587
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.